Cancel
Accent Therapeutics
See Linkedin
Accent Therapeutics Employees
10 people indexed:
-
Ann Boriack-Sjodin
Senior Vice President, Molecular Discovery
7y2fy2pgul4h8q1@uvflv3qg.zpv Sign up to see email179u1w2yl6yw5yy@vquphwll.g2f Sign up to see email -
pls508z@2v6pfjjj.l63 Sign up to see email
-
1f3q9b@q2f89yvd.y05 Sign up to see email
-
zl33p6f@9ys5l6yv.9j5 Sign up to see email
-
Robert A. Copeland
Founder, President, Chief Scientific Officer
5h.778b0fuq@058s8s0w.9qf Sign up to see emailq3.gis5g837@5z8yqi18.vs8 Sign up to see email -
38zw27y@759h6995.g85 Sign up to see email
-
ihz4zh6j@9buzlu7p.27v Sign up to see email
-
Stephen Blakemore
Vice President, Biological & Translational Sciences
81hvgq5vqp@v22151wi.hjq Sign up to see email8q56y8hip3@df15yvfg.phz Sign up to see email -
6bq9k2f@r7rd7kpz.ywy Sign up to see email
-
2v.wbwr@q5kw77gk.b3d Sign up to see email
Accent Therapeutics Company Information
Accent Therapeutics, located at 1050 Waltham St., Suite 201, Lexington, MA 02421, focuses on developing small molecule therapeutics that target RNA-modifying proteins (RMPs) for cancer treatment. Their pipeline includes first-in-class and best-in-class programs aimed at addressing significant unmet medical needs in cancer therapy. The lead programs target DHX9 and KIF18A, which are focused on cancers with high unmet clinical needs. Accent Therapeutics has achieved ‘Green Lab’ status through the My Green Lab Certification Program, reflecting their commitment to reducing the environmental footprint of their research. The company has partnered with AstraZeneca to discover and develop novel cancer therapeutics targeting RNA-modifying proteins. In 2024, Accent Therapeutics presented data supporting their two lead programs at the AACR Annual Meeting. They have also raised $75 million in Series C financing to advance their small molecule precision cancer therapies.
Report inaccurate information
Report inaccurate information